Apraglutide
Investigational — GLP-2 analog for SBS — not approved.
Ref $ —reference only
ApraglutideIn clinical trials · Not yet FDA-approvedWhat it's for
Investigational — GLP-2 analog for SBS — not approved.
What it's for
Apraglutide is an still being studied next-generation GLP-2 medicine that turns a receptor signal on with extended how long it stays active in the body.
What it does for the body
It is studied to improve intestinal absorption in short bowel syndrome. Not approved. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
GLP-2 receptors (lock-and-key landing spots on cells) activation supports lining of the gut growth and absorptive capacity, similar in class to teduglutide but with different how long it lasts in the body (how long it lasts in the body) design. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Apraglutide is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Apraglutide — FDA.gov search
- ClinicalTrials.gov search: Apraglutide — U.S. clinical trials registry
- Drugs@FDA search: Apraglutide — FDA drug database (if approved)
- PubMed search: Apraglutide — NCBI PubMed
- PubMed Central search: Apraglutide — NCBI PMC
Reference
No ref on file.